Mr. Speaker, the innovative pharmaceutical industry spends $40 million a year in drug review fees. Does the minister believe that she is able to meet the review deadlines and, if not, should Health Canada not reimburse the review fees for lack of efficiency?
In the House of Commons on February 18th, 2003. See this statement in context.